Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.48
18.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Yantai Dongcheng Biochemicals Co Ltd
Selling, General & Administrative
Yantai Dongcheng Biochemicals Co Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Y
|
Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
|
Selling, General & Administrative
-¥682.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-20%
|
|
|
Beigene Ltd
HKEX:6160
|
Selling, General & Administrative
-¥10.9B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Selling, General & Administrative
-¥1.9B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Selling, General & Administrative
-¥781.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-17%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Selling, General & Administrative
-¥3.5B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-28%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Selling, General & Administrative
-¥397.2m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Yantai Dongcheng Biochemicals Co Ltd
Glance View
Yantai Dongcheng Biochemicals Co., Ltd. engages in the research, development, production and sales of heparin sodium bulk drug and chondroitin sulfate. The company is headquartered in Yantai, Shandong and currently employs 2,128 full-time employees. The company went IPO on 2012-05-25. The Company’s main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The firm distributes its products in domestic market and to overseas markets.
See Also
What is Yantai Dongcheng Biochemicals Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-682.5m
CNY
Based on the financial report for Jun 30, 2024, Yantai Dongcheng Biochemicals Co Ltd's Selling, General & Administrative amounts to -682.5m CNY.
What is Yantai Dongcheng Biochemicals Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-20%
Over the last year, the Selling, General & Administrative growth was 20%. The average annual Selling, General & Administrative growth rates for Yantai Dongcheng Biochemicals Co Ltd have been 9% over the past three years , 4% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
